Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies

Volume: 21, Issue: 6, Pages: 509 - 520
Published: Dec 1, 2021
Abstract
Triple negative breast cancer (TNBC) represents 15% to 20% of all primary breast cancers and is the most aggressive subtype of breast cancer. There has been rapid progress in targeted therapy and biomarker development to identify the optimal treatments for TNBC. To update recent developments, this article comprehensively reviews molecular classification and biomarkers of TNBC and targeted therapy developments in immunotherapy, PARP and AKT...
Paper Details
Title
Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies
Published Date
Dec 1, 2021
Volume
21
Issue
6
Pages
509 - 520
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.